Amylin Pharmaceuticals

Petauri™ Announces 2 Key Hires at Petauri Advisors

Retrieved on: 
Monday, April 29, 2024
CVS, University, Pharmacy, Amylin Pharmaceuticals, Mentorship, Care Act 2014, Pharmacist, Medicare Part D, Novartis, SVP, Pfizer, Senior, AMCP, Medicare, Marketing, MBA, Affordable Care Act, Pharmaceutical industry

NASHVILLE, Tenn., April 29, 2024 /PRNewswire/ -- Petauri Advisors, a strategic life sciences consulting business unit of Petauri, a leading purpose-built pharmaceutical services platform, announced today that it has added to its executive ranks 2 experienced leaders who bring extensive market access experience and expertise comprising implementation of Medicare Part D, the Affordable Care Act, and brand marketing.

Key Points: 
  • Petauri Advisors has added Gina Valerio and Joe Honcz to its ranks as VP and SVP, respectively.
  • Given her deep expertise in market access and brand marketing strategy, along with her profound understanding of the evolving healthcare landscape, Gina will be a highly valued partner to Petauri Advisors clients navigating today's market access challenges.
  • Before joining Petauri, Gina provided strategic market access consultative services to various pharmaceutical and life sciences companies in the San Diego area.
  • "With their proven track record across the continuum of managed care, Gina and Joe bring valuable and diverse experience to Petauri Advisors," said Steve O'Malley, President, Petauri Advisors.

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Health, Medical Devices, Diabetes, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Research, Control, Overweight, Vivani, Symantec Endpoint Protection, Obesity, Visual perception, Medicine, Amylin Pharmaceuticals, Acceleration, Chemistry, New Drug Application, Patient, Conditional sentence, Weight loss, Stroke, Mouse, Acquisition, Second Sight, Insurance, Trial of the century, Alkermes, Risk, Investment, Injection, Depreciation, Food, Pharmaceutical industry

Research and development expenses: Research and development expenses during the fourth quarter of 2023 were $4.7 million, compared to $4.4 million during the fourth quarter of 2022.

Key Points: 
  • Research and development expenses: Research and development expenses during the fourth quarter of 2023 were $4.7 million, compared to $4.4 million during the fourth quarter of 2022.
  • General and administrative expenses: General and administrative expenses during the fourth quarter of 2023 were $1.5 million, compared to $3.4 million during the fourth quarter of 2022.
  • Other income (expense): Other income (expense), net during the fourth quarter of 2023 was $0.2 million, compared to $0.5 million during the fourth quarter of 2022.
  • Net Loss: The net loss during the fourth quarter of 2023 was $6.0 million, compared to $7.3 million during the fourth quarter of 2022.

Vivani Medical Appoints Daniel Bradbury to its Board of Directors

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Pharmaceutical, Health, Acquisition, Medicine, Illumina, Inc., Obesity, Marketing, Amylin Pharmaceuticals, Audit committee, University, University of Nottingham, Therapy, Management, DSM-IV codes, Bristol Myers Squibb, Vivani, Pharmaceutical industry

Vivani Medical, Inc. (Nasdaq: VANI ) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced the appointment of long-time industry veteran Daniel Bradbury to its Board of Directors.

Key Points: 
  • Vivani Medical, Inc. (Nasdaq: VANI ) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced the appointment of long-time industry veteran Daniel Bradbury to its Board of Directors.
  • Bradbury serves on the board of directors of Castle Biosciences, Inc. and Equillium, Inc., and several private companies and philanthropic organizations.
  • Bradbury previously served on the board of directors of Biocon Limited, Corcept Therapeutics Inc., Geron Inc., Illumina Inc. and Intercept Pharmaceuticals Inc.
  • In addition to his new role as Board Director, Bradbury will serve on the Audit Committee of the Vivani Medical Board.

RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development

Retrieved on: 
Monday, December 11, 2023
Amylin Pharmaceuticals, Biotechnology, Sale, Eli Lilly, Strategic management, OTC Markets Group, Therapy, Business development, RespireRx, Decision Sciences, Dronabinol, Eli Lilly and Company

Mr. Clodfelter will initially lead the business development efforts with respect to dronabinol, the lead asset of ResolutionRx Ltd, a wholly-owned Australian subsidiary of the Company.

Key Points: 
  • Mr. Clodfelter will initially lead the business development efforts with respect to dronabinol, the lead asset of ResolutionRx Ltd, a wholly-owned Australian subsidiary of the Company.
  • Mr. Clodfelter will collaborate with Jeff Eliot Margolis, the Company’s Senior Vice President, Chief Financial Officer, Treasurer and Secretary in driving these efforts.
  • He previously held positions at Eli Lilly and Co. in Corporate Strategy and Business Development.
  • He was at Amylin Pharmaceuticals in New Product Planning and Decision Sciences and was involved in multiple business development activities.

Perpetual Medicines Completes $8 Million Seed Round to Advance Integrated Computational Design-Synthesis Platform for Peptide Drug Discovery

Retrieved on: 
Friday, December 1, 2023
Oncology, Health, Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Intarsia, Initial public offering, Amylin Pharmaceuticals, GSK plc, Vancomycin, Senior, Head, Protein, APS, Artificial intelligence, Machine learning, Medication, Eli Lilly, Therapy, Perpetual, Eli Lilly and Company, MD, Harvard Medical School, Deep learning, Drug discovery, Drug development, Spotlight Innovation, Doctor of Philosophy, Incretin, Autoimmunity, Fine chemical, Management, Chemistry

Perpetual Medicines today announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for peptide drug discovery.

Key Points: 
  • Perpetual Medicines today announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for peptide drug discovery.
  • “Perpetual Medicines is capitalizing on recent advances in computational modeling based on artificial intelligence, deep learning and machine learning that enable access for the first time to the enormous, untapped peptide chemical space for drug discovery,” said Dr. Blanchard.
  • This approach has the potential to accelerate peptide drug discovery, reduce cost, and increase the quality of drug candidates.
  • Ved Srivastava, PhD, Chief Technology Officer – Dr. Srivastava brings to Perpetual Medicines more than 25 years of experience in the discovery and development of peptide therapeutics.

Velia Therapeutics Appoints Michael York as Chief Business Officer

Retrieved on: 
Thursday, December 14, 2023
University, Proteome, Economics, Amylin Pharmaceuticals, Research, SAN, AstraZeneca, Therapy, Patient, Strategic planning, IPO, MBA, MD, Growth, San Diego State University, Fine chemical, Management, Microprotein, Velia, Merck, Orexigen Therapeutics

SAN DIEGO, Dec. 14, 2023 /PRNewswire/ -- Velia Therapeutics, a biotechnology company focused on the discovery and development of a new generation of protein-based therapeutics that address the underlying causes of difficult-to-treat diseases, today announced that Michael York has joined the organization as chief business officer. Mr. York will lead business development, research collaborations and strategic planning to drive growth of the company's microprotein-based pipeline of transformative therapeutics.

Key Points: 
  • Mr. York brings over 30 years of experience leading business development, strategic planning and commercial functions across pharmaceutical and biotech companies
    SAN DIEGO, Dec. 14, 2023 /PRNewswire/ -- Velia Therapeutics, a biotechnology company focused on the discovery and development of a new generation of protein-based therapeutics that address the underlying causes of difficult-to-treat diseases, today announced that Michael York has joined the organization as chief business officer.
  • Mr. York will lead business development, research collaborations and strategic planning to drive growth of the company's microprotein-based pipeline of transformative therapeutics.
  • "I am pleased to welcome Michael to Velia as chief business officer, where he will play a critical role in our portfolio planning efforts to prioritize microproteins that we've identified hidden in the dark matter of the human proteome," said John McHutchison, AO, MD, president and chief executive officer at Velia Therapeutics.
  • Mr. York has more than 30 years of experience in business development, corporate strategy, and commercial leadership across a breadth of therapeutic categories.

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Retrieved on: 
Monday, October 23, 2023
Oncology, Health, Other Science, Pharmaceutical, Science, Biotechnology, Persephone, Allergy, United Kingdom, Veronica, Janssen, University of Nottingham, Amylin Pharmaceuticals, DSM-IV codes, Management, Diabetes, Acquisition, General partnership, Research, Infant, Trustee, Keck Graduate Institute, Marketing, Executive, Bristol Myers Squibb, University, Bachelor of Pharmacy, Education, Therapy, Intercept Pharmaceuticals, Pharmaceutical industry, Pharmacy

Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors.

Key Points: 
  • Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors.
  • Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in cancer treatment response, and our AMBROSIA food-as-medicine study.
  • “As Chair, Dan brings his vast experience as a serial entrepreneur, spanning both public and private biotechs, to our company.
  • In addition, Mr. Bradbury serves on the Keck Graduate Institute’s Board of Trustees and the University of California San Diego’s Rady School of Management Dean’s Advisory Council.

Walgreens Boots Alliance Announces Leadership Transition

Retrieved on: 
Friday, September 1, 2023
Discount, Variety, Specialty, Convenience Store, Other Health, Health, Cosmetics, Pharmaceutical, General Health, Retail, Vaccine, Lead, Walgreens Boots Alliance, University, Diabetes, Pharmacy, Harvard University, Culture, COVID-19, MBA, WBA, Eli Lilly, COVID-19 vaccine, Healthcare in the United States, Harvard Business School, Guidant, Faculty, Growth, Amylin Pharmaceuticals, Eli Lilly and Company, Office of the President, Stefano Pessina, Cardiology, EPS, Rosalind Brewer, Management, Walgreens

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that the Board of Directors and Rosalind Brewer have mutually agreed that Ms.

Key Points: 
  • Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that the Board of Directors and Rosalind Brewer have mutually agreed that Ms.
  • Brewer has agreed to continue to advise WBA while the Company conducts a search for a permanent CEO.
  • Roz navigated the Company through the global pandemic, overseeing the critical rollout of vaccines in Walgreens pharmacies and to high-risk populations across the country.
  • Brewer said, “I am grateful to have had the opportunity to lead Walgreens Boots Alliance and to work alongside such talented and dedicated colleagues.

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

Retrieved on: 
Thursday, August 31, 2023
AWARD, The New England Journal of Medicine, Medical Affairs Bureau, Cell Metabolism, University, MOA, Therapy, Diabetes, T1D, Diabetes Care, STEP, Coronavirus Scientific Advisory Board, CMO, CDO, Eli Lilly, AML, Morris, Publication, Patient, DSM-IV codes, Cancer, Chief medical informatics officer, DURATION, Amylin Pharmaceuticals, Johnson & Johnson, Safety, Disease, Pharmaceutical industry, Endocrinology, Lancet, Pfizer, Osteopathic medicine in Canada

as Chief Medical Officer (CMO).

Key Points: 
  • as Chief Medical Officer (CMO).
  • Steve Morris, M.D., will transition to the new role of Chief Development Officer (CDO), where he will continue to lead clinical development of Biomea’s oncology portfolio, including BMF-219, BMF-500 and several early-stage oncology research candidates.
  • “The addition of Juan to the Biomea Leadership team is an important and exciting event for the company.
  • Our appointment of Juan to lead clinical development of BMF-219 in diabetes is a cornerstone of this strategy,” said Thomas Butler, CEO and Chairman of Biomea.

SD2, Local STEM Nonprofit, Adds Two Members to Board

Retrieved on: 
Thursday, August 3, 2023
Technology, Other Technology, Other Education, Continuing, Training, Primary, Secondary, Other Science, Science, Education, BIO, Intellectual property, General counsel, Life, Face, Internet of things, Neurocrine Biosciences, Neurocrine, Mentorship, Associate, Student, Biotechnology Innovation Organization, Machine learning, Engineering, Corporation, Amylin Pharmaceuticals, AI, SD2, Management, STEM

San Diego Squared (SD2), a local nonprofit dedicated to empowering underrepresented students in STEM (science, technology, engineering, and math) is pleased to announce the addition of two new board members to their already innovative group of local leaders, Alex Bolante and Darin M. Lippoldt.

Key Points: 
  • San Diego Squared (SD2), a local nonprofit dedicated to empowering underrepresented students in STEM (science, technology, engineering, and math) is pleased to announce the addition of two new board members to their already innovative group of local leaders, Alex Bolante and Darin M. Lippoldt.
  • "We are thrilled to welcome new, high-caliber leaders to our Board to continue our mission of empowering underrepresented students in the San Diego community,” remarked Bill Rastetter, Founder of San Diego Squared and Chairman of the Board.
  • Passionate about STEM, he also serves as the chair of the Biotechnology Innovation Organization (BIO) General Counsels’ Committee for this current year.
  • He is excited to bring his life and career experiences to the SD2 Board to help drive change for underrepresented students.